search
Back to results

Spanish Cohort for the Study of the Effect of CPAP in Hypertension (CEPECTA)

Primary Purpose

Sleep Apnea, Hypertension

Status
Unknown status
Phase
Not Applicable
Locations
Spain
Study Type
Interventional
Intervention
Nasal continuos positive airway pressure
Sponsored by
Sociedad Española de Neumología y Cirugía Torácica
About
Eligibility
Locations
Outcomes
Full info

About this trial

This is an interventional treatment trial for Sleep Apnea focused on measuring Sleep apnea, Hypertension, CPAP

Eligibility Criteria

18 Years - 75 Years (Adult, Older Adult)All SexesDoes not accept healthy volunteers

Inclusion Criteria: Patients, both sexes from 18 to 75 years old, with clinical suspected of OSAH defined by an apnea-hypopnea index > 15 and having a recent diagnosis of hypertension which have not received any pharmacological treatment for hypertension. Exclusion Criteria: Inclusion Criteria: Patients with clinical suspected of OSAH defined by an apnea-hypopnea index > 15 and having a recent diagnosis of hypertension which have not received any pharmacological treatment for hypertension. Exclusion Criteria: Severe excessive daytime sleepiness; professional drivers; pregnant women; alcohol consumption more than 100 gr. Ethanol per day; sedative medication; psychiatric illness; malignant or complicated hypertension; renal insufficiency; severe chronically ilness or malignant ilness; severe craniomandibular disease

Sites / Locations

  • Unit of Research. Hospital TxagorritxuRecruiting

Outcomes

Primary Outcome Measures

Effect of CPAP in 24 hours blood pressure monitoring
effect of CPAP y quality of life and clinical aspects

Secondary Outcome Measures

effect of CPAP in biologic mediators

Full Information

First Posted
September 12, 2005
Last Updated
December 22, 2005
Sponsor
Sociedad Española de Neumología y Cirugía Torácica
search

1. Study Identification

Unique Protocol Identification Number
NCT00202527
Brief Title
Spanish Cohort for the Study of the Effect of CPAP in Hypertension (CEPECTA)
Official Title
Efficacy of the Treatment With Nasal Positive Continuous Airway Pressure to Reduce the Arterial Blood Pressure in Patients With Apneas-Hypopneas During the Sleep and Systemic Hypertension
Study Type
Interventional

2. Study Status

Record Verification Date
September 2005
Overall Recruitment Status
Unknown status
Study Start Date
January 2005 (undefined)
Primary Completion Date
undefined (undefined)
Study Completion Date
September 2005 (undefined)

3. Sponsor/Collaborators

Name of the Sponsor
Sociedad Española de Neumología y Cirugía Torácica

4. Oversight

5. Study Description

Brief Summary
AIMS:To know the effects of the treatment with nasal positive continuous airway pressure (CPAP) on systemic blood pressure and the expression of biological mediators, in systemic hypertension of recent diagnostic, whose have an apnea-hypopnea index > 15. METHODOLOGY: DESIGN: Prospective, multicenter, randomized study, of parallel groups and controlled with placebo, in patients diagnosed of systemic hypertension (SH) with an apnea-hypopnea index, by conventional polysomnography > 15. A total of 340 patients with recently diagnosed of SH and without any pharmacological treatment will be studied. All patients will be randomized to receive, alternatively, CPAP treatment with optimal pressure titled with a proved system, or Sham-CPAP for 12 weeks. MEASUREMENTS: A) Conventional polysomnography at baseline: B) Clinic: sleepiness (ATS, Basic Nordic Sleep Questionnaire and Epworth), quality of life (EuroQol); C) 24 hour blood pressure monitoring; D) Expression of biological mediators in blood: general determinations, endothelial, inflammatory, lipid, renin-angiotensin-aldosterone and adrenergic mediators. ANALYSIS. Baseline measurements of all the variables will be compared with the situation at six and twelve weeks. We will use the chi square test and the Fisher´s exact test (categorical variables), the t test for continous variables and repeated measures ANCOVA for the primary objective. The analyses will be done under the criterion of intention to treat and for protocol. The variables will be controlled by the compliance with the CPAP..

6. Conditions and Keywords

Primary Disease or Condition Being Studied in the Trial, or the Focus of the Study
Sleep Apnea, Hypertension
Keywords
Sleep apnea, Hypertension, CPAP

7. Study Design

Primary Purpose
Treatment
Study Phase
Not Applicable
Interventional Study Model
Parallel Assignment
Masking
Double
Allocation
Randomized
Enrollment
340 (false)

8. Arms, Groups, and Interventions

Intervention Type
Device
Intervention Name(s)
Nasal continuos positive airway pressure
Primary Outcome Measure Information:
Title
Effect of CPAP in 24 hours blood pressure monitoring
Title
effect of CPAP y quality of life and clinical aspects
Secondary Outcome Measure Information:
Title
effect of CPAP in biologic mediators

10. Eligibility

Sex
All
Minimum Age & Unit of Time
18 Years
Maximum Age & Unit of Time
75 Years
Accepts Healthy Volunteers
No
Eligibility Criteria
Inclusion Criteria: Patients, both sexes from 18 to 75 years old, with clinical suspected of OSAH defined by an apnea-hypopnea index > 15 and having a recent diagnosis of hypertension which have not received any pharmacological treatment for hypertension. Exclusion Criteria: Inclusion Criteria: Patients with clinical suspected of OSAH defined by an apnea-hypopnea index > 15 and having a recent diagnosis of hypertension which have not received any pharmacological treatment for hypertension. Exclusion Criteria: Severe excessive daytime sleepiness; professional drivers; pregnant women; alcohol consumption more than 100 gr. Ethanol per day; sedative medication; psychiatric illness; malignant or complicated hypertension; renal insufficiency; severe chronically ilness or malignant ilness; severe craniomandibular disease
Central Contact Person:
First Name & Middle Initial & Last Name or Official Title & Degree
JOAQUIN DURAN-CANTOLLA, MD
Phone
34 945 007308
Email
joaquin.duran@wanadoo.es
Overall Study Officials:
First Name & Middle Initial & Last Name & Degree
JOAQUIN DURAN-CANTOLLA, MD
Organizational Affiliation
Sociedad Española de Cirugía Torácica
Official's Role
Principal Investigator
Facility Information:
Facility Name
Unit of Research. Hospital Txagorritxu
City
Vitoria
State/Province
Alava
ZIP/Postal Code
01009
Country
Spain
Individual Site Status
Recruiting
Facility Contact:
First Name & Middle Initial & Last Name & Degree
JOAQUIN DURAN-CANTOLLA, MD
Phone
34 945 007308
Email
joaquin.duran@wanadoo.es
First Name & Middle Initial & Last Name & Degree
JOAQUIN DURAN-CANTOLLA, MD

12. IPD Sharing Statement

Citations:
PubMed Identifier
21106625
Citation
Duran-Cantolla J, Aizpuru F, Montserrat JM, Ballester E, Teran-Santos J, Aguirregomoscorta JI, Gonzalez M, Lloberes P, Masa JF, De La Pena M, Carrizo S, Mayos M, Barbe F; Spanish Sleep and Breathing Group. Continuous positive airway pressure as treatment for systemic hypertension in people with obstructive sleep apnoea: randomised controlled trial. BMJ. 2010 Nov 24;341:c5991. doi: 10.1136/bmj.c5991.
Results Reference
derived

Learn more about this trial

Spanish Cohort for the Study of the Effect of CPAP in Hypertension (CEPECTA)

We'll reach out to this number within 24 hrs